These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29879072)

  • 1. Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review.
    Shirai T; Onishi A; Waki D; Saegusa J; Morinobu A
    Medicine (Baltimore); 2018 Jun; 97(23):e11045. PubMed ID: 29879072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis: a case report.
    Fujiwara Y; Ito K; Takamura A; Nagata K
    J Med Case Rep; 2018 Oct; 12(1):295. PubMed ID: 30293532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging.
    Nara M; Komatsuda A; Itoh F; Kaga H; Saitoh M; Togashi M; Kameoka Y; Wakui H; Takahashi N
    Intern Med; 2017; 56(10):1247-1252. PubMed ID: 28502946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy.
    Hiramatsu S; Ohmura K; Tsuji H; Kawabata H; Kitano T; Sogabe A; Hashimoto M; Murakami K; Imura Y; Yukawa N; Yoshifuji H; Fujii T; Takaori-Kondo A; Mimori T
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(1):64-71. PubMed ID: 27181237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
    Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
    Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAFRO syndrome: A disease that known is half cured.
    Chen T; Feng C; Zhang X; Zhou J
    Hematol Oncol; 2023 Aug; 41(3):310-322. PubMed ID: 36148768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.
    Zhou Q; Zhang Y; Zhou G; Zhu J
    BMC Nephrol; 2020 Nov; 21(1):499. PubMed ID: 33225930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease.
    Kubokawa I; Yachie A; Hayakawa A; Hirase S; Yamamoto N; Mori T; Yanai T; Takeshima Y; Kyo E; Kageyama G; Nagai H; Uehara K; Kojima M; Iijima K
    BMC Pediatr; 2014 Jun; 14():139. PubMed ID: 24890946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus Treatment for TAFRO Syndrome.
    Shirai T; Ichikawa S; Saegusa J
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38791031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
    Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
    Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with Bilateral Adrenal Hemorrhage in Two Caucasian Patients.
    Ducoux G; Guerber A; Durel CA; Asli B; Fadlallah J; Hot A
    Am J Case Rep; 2020 Apr; 21():e919536. PubMed ID: 32249274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful rituximab treatment of TAFRO syndrome refractory to glucocorticoids and tocilizumab].
    Sumi C; Toki Y; Funayama T; Saito T; Hatayama M; Yamamoto M; Shindo M; Yuzawa S; Tanino M; Okumura T
    Rinsho Ketsueki; 2023; 64(4):265-270. PubMed ID: 37121770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review.
    Sakai K; Maeda T; Kuriyama A; Shimada N; Notohara K; Ueda Y
    Mod Rheumatol; 2018 May; 28(3):564-569. PubMed ID: 26886414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study.
    Nishimura Y; Hanayama Y; Fujii N; Kondo E; Otsuka F
    Intern Med J; 2020 Feb; 50(2):184-191. PubMed ID: 31211492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review.
    Grange L; Chalayer E; Boutboul D; Paul S; Galicier L; Gramont B; Killian M
    Autoimmun Rev; 2022 Aug; 21(8):103137. PubMed ID: 35803499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed diagnosis of TAFRO syndrome: A case report.
    Qiao Y; Zhang X; Xu R; Jia X; Wang Q
    Medicine (Baltimore); 2024 Aug; 103(31):e39148. PubMed ID: 39093747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAFRO syndrome: 2 cases and review of the literature.
    Kawashima M; Usui T; Okada H; Mori I; Yamauchi M; Ikeda T; Kajita K; Kito Y; Miyazaki T; Fujioka K; Ishizuka T; Morita H
    Mod Rheumatol; 2017 Nov; 27(6):1093-1097. PubMed ID: 26052800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of progressive renal involvement in TAFRO syndrome: A case report and literature review.
    Tanaka M; Tsujimoto H; Yamamoto K; Shimoda S; Oka K; Takeoka H
    Medicine (Baltimore); 2017 Oct; 96(40):e8216. PubMed ID: 28984775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
    Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAFRO Syndrome.
    Igawa T; Sato Y
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.